BiotechTube

Mogamulizumab

Phase 2Active
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cutaneous T-Cell Lymphoma, Relapsed

Conditions

Cutaneous T-Cell Lymphoma, Relapsed, Cutaneous T-Cell Lymphoma Refractory

Trial Timeline

Aug 16, 2021 → May 1, 2025

NCT ID
NCT04745234

About Mogamulizumab

Mogamulizumab is a phase 2 stage product being developed by Kyowa Kirin for Cutaneous T-Cell Lymphoma, Relapsed. The current trial status is active. This product is registered under clinical trial identifier NCT04745234. Target conditions include Cutaneous T-Cell Lymphoma, Relapsed, Cutaneous T-Cell Lymphoma Refractory.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT06285370ApprovedActive
NCT04745234Phase 2Active

Competing Products

20 competing products in Cutaneous T-Cell Lymphoma, Relapsed

See all competitors
ProductCompanyStageHype Score
ONTAK (denileukin difitox, DAB389IL-2)EisaiApproved
85
ONTAKEisaiApproved
85
E7777 9 mcg/kgEisaiPhase 3
77
ONTAKEisaiApproved
85
MogamulizumabKyowa KirinApproved
85
Mogamulizumab + Brentuximab vedotinKyowa KirinPhase 1
33
KW-0761 + VorinostatKyowa KirinPhase 3
77
EnzastaurinEli LillyPhase 2
52
Clopidogrel + TicagrelorAstraZenecaApproved
85
PembrolizumabMerckPhase 2
52
Comparator: vorinostatMerckPre-clinical
23
PembrolizumabMerckPhase 2
52
TR701 FAMerckPhase 2
52
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 MonthsMerckPhase 2
52
PembrolizumabMerckPhase 2
52
Tulisokibart + PlaceboMerckPhase 2
52
Aspirin + Ipilimumab + PembrolizumabMerckPhase 2
52
Pembrolizumab + MogamulizumabMerckPhase 2
52
TR-701 FA + LinezolidMerckPhase 3
77
Pimasertib + DacarbazineMerckPhase 2
52

Other Products from Kyowa Kirin

KRN23Approved
85
Istradefylline PillApproved
85
MogamulizumabApproved
85
KRN23Approved
85
KHK4827-Active + KHK4827-PlaceboApproved
85